Suresnes (France), February 27th, 2025 – Servier announces the appointment of Nitza Thomasson as Executive Director R&D Neurology effective March 1, 2025.
In her new role, Nitza Thomasson will be responsible for the Group’s R&D strategy in the field of neurology, leading and accelerating the research and development of new treatments for patients with rare neurological diseases. She will play a key role in strengthening the R&D pipeline and will work closely with the R&D teams, as well as with all the Group’s other business lines and external strategic partners. As part of its 2030 strategy, the Servier Group will dedicate significant resources and investments to build a robust and promising R&D pipeline in the field of neurology. Through new treatments, the aim is to meet the most important medical needs of these often devastating neurological diseases.
Nitza Thomasson has recognized international expertise in neuroscience with a multidisciplinary background in R&D within the pharmaceutical industry and at biotechnology companies. She holds a master’s degree (École Polytechnique, ENS) and a PhD in Neuroscience (Paris Sorbonne). She then conducted postdoctoral research at Northwestern University (Chicago, Illinois, USA) and Hôpital Sainte-Anne (Paris). As an entrepreneur driven by innovation, Nitza co-founded BrainEver and GenSight Biologics. She has also held executive positions at Sanofi, Fovea, and Tissium. Finally, she founded NTZConsulting, supporting a large number of companies in their pharmaceutical development strategies for more than seven years. Her return to Servier marks a new stage, after serving as Head of Biological Studies and Head of Clinical Studies in neurology from November 2001 to April 2009. With a solid background in leadership, research management and the development of innovative therapies, she brings a strategic and scientific vision to accelerate the Group’s expansion in neurology.